Compare DKI & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DKI | APVO |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | Hong Kong | United States |
| Employees | 19 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 8.3M |
| IPO Year | N/A | 2023 |
| Metric | DKI | APVO |
|---|---|---|
| Price | $5.91 | $4.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 184.9K | 26.3K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,114,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.50 |
| 52 Week High | $11.80 | $13.11 |
| Indicator | DKI | APVO |
|---|---|---|
| Relative Strength Index (RSI) | 71.90 | 50.82 |
| Support Level | $4.82 | $4.29 |
| Resistance Level | $6.80 | $5.66 |
| Average True Range (ATR) | 0.80 | 0.33 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 57.21 | 65.17 |
Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.